Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

Basit Öğe Kaydı
dc.authorid0000-0002-7071-2471
dc.contributor.authorVokes, Natalie I.
dc.contributor.authorGandara, David R.
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorBondarenko, Igor
dc.contributor.authorOzguroglu, Mustafa
dc.date.accessioned2025-05-10T19:27:40Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 02-06, 2023 -- Chicago, IL
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofi
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc. and Sanofi.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7025
dc.identifier.volume41
dc.identifier.wosWOS:001053772003690
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleCirculating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu